AbbVie Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 16.40 B

AbbVie Inc. Operating Cash Flow is USD 16.40 B for the Trailing 12 Months (TTM) ending March 31, 2025, a -27.70% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • AbbVie Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 22.69 B, a -6.36% change year over year.
  • AbbVie Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 24.23 B, a 6.23% change year over year.
  • AbbVie Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 22.81 B, a 22.29% change year over year.
  • AbbVie Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 18.65 B, a 32.06% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities